Latin American open-label study with rabeprazole in patients with functional dyspepsia. Mexican Rabeprazole Investigators Group.
This multicenter, open-label study assessed the clinical efficacy and tolerability of the proton-pump inhibitor rabeprazole 20 mg once daily in 189 patients with functional dyspepsia and normal findings on upper endoscopy. The clinical efficacy rate was 86% after only 4 weeks of treatment, and symptoms remained under control at the end of 4 weeks without treatment. Rabeprazole was well tolerated and was associated with a low incidence (8%) of mild, transient adverse events.
Mundo-Gallardo
F
F
Hospital Angeles del Pedregal, Mexico City, Mexico.
De Mezerville-Cantillo
L
L
Burgos-Quiroz
H
H
Izquierdo
E
E
Chang-Mayorga
J
J
Azteguieta
L
L
Passarrelli-Sandhoff
L F
LF
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors*; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D006180:Proton-Translocating ATPases; D009853:Omeprazole